Vijay Pande Leaves a16z’s $4 Billion Biotech Arm to Launch AI-Focused Venture

Vijay Pande has departed from Andreessen Horowitz’s (a16z) biotech division, which manages around $4 billion in assets, to establish a new, smaller firm centered on artificial intelligence. According to TechCrunch, this transition took place last year, marking a strategic shift from biotech to AI-driven ventures.

The new company, named VZVC, is described as an AI-native firm, indicating a focus on leveraging cutting-edge AI technologies rather than traditional biotech investments. This move underscores a growing trend among investors and founders to pivot towards AI innovation following the sector’s recent surge in interest and capital.

For Japanese market participants, this development highlights the evolving landscape of venture capital priorities, where AI is increasingly becoming a key area of focus alongside established fields like biotech and equities.